Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) Cyclically Adjusted FCF per Share: ¥-0.44 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600513 Jiangsu Lianhuan Pharmaceutical Co Ltd SHSE:600513
63 GF Score
Price ¥16.64
GF Value ¥13.83
Valuation Modestly Overvalued
! 10 Warning Signs
View Full Analysis

What is Jiangsu Lianhuan Pharmaceutical Co Cyclically Adjusted FCF per Share?

Jiangsu Lianhuan Pharmaceutical Co SHSE:600513 -4.64% 63 Cyclically Adjusted FCF per Share is ¥-0.44 as of Mar. 2026. GuruFocus rates SHSE:600513 with a GF Score™ of 63/100 and a GF Value™ of ¥13.83 (Modestly Overvalued). The stock has 10 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Jiangsu Lianhuan Pharmaceutical Co's adjusted free cash flow per share for the three months ended in Mar. 2026 was ¥-0.432. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is ¥-0.44 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -27.00% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was -29.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Jiangsu Lianhuan Pharmaceutical Co was 91.30% per year. The lowest was -135.10% per year. And the median was -27.00% per year.

As of today (2026-08-21), Jiangsu Lianhuan Pharmaceutical Co's current stock price is ¥16.64. Jiangsu Lianhuan Pharmaceutical Co's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was ¥-0.44. Jiangsu Lianhuan Pharmaceutical Co's Cyclically Adjusted Price-to-FCF of today is .

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Jiangsu Lianhuan Pharmaceutical Co was 248.00. The lowest was 110.67. And the median was 146.86.


Jiangsu Lianhuan Pharmaceutical Co  (SHSE:600513) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Jiangsu Lianhuan Pharmaceutical Co was 248.00. The lowest was 110.67. And the median was 146.86.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Jiangsu Lianhuan Pharmaceutical Co Cyclically Adjusted FCF per Share Related Terms


Jiangsu Lianhuan Pharmaceutical Co Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Jiangsu Lianhuan Pharmaceutical Co's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jiangsu Lianhuan Pharmaceutical Co Cyclically Adjusted FCF per Share Chart

Jiangsu Lianhuan Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.13 -0.20 -0.21 -0.29 -0.41

Jiangsu Lianhuan Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.34 -0.39 -0.42 -0.41 -0.44

SHSE:600513 vs ZTS: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Jiangsu Lianhuan Pharmaceutical Co's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jiangsu Lianhuan Pharmaceutical Co Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Jiangsu Lianhuan Pharmaceutical Co's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Jiangsu Lianhuan Pharmaceutical Co's Cyclically Adjusted Price-to-FCF falls into.


SHSE:600513
63GF Score
Jiangsu Lianhuan Pharmaceutical Co Ltd SHSE:600513
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jiangsu Lianhuan Pharmaceutical Co Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Jiangsu Lianhuan Pharmaceutical Co's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.432/116.3033*116.3033
=-0.432

Current CPI (Mar. 2026) = 116.3033.

Jiangsu Lianhuan Pharmaceutical Co Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 0.084 101.400 0.096
201609 0.048 102.400 0.055
201612 0.056 102.600 0.063
201703 -0.084 103.200 -0.095
201706 0.050 103.100 0.056
201709 -0.019 104.100 -0.021
201712 -0.117 104.500 -0.130
201803 -0.118 105.300 -0.130
201806 -0.051 104.900 -0.057
201809 -0.170 106.600 -0.185
201812 -0.438 106.500 -0.478
201903 -0.300 107.700 -0.324
201906 -0.055 107.700 -0.059
201909 -0.206 109.800 -0.218
201912 -0.060 111.200 -0.063
202003 -0.344 112.300 -0.356
202006 0.065 110.400 0.068
202009 0.049 111.700 0.051
202012 -0.074 111.500 -0.077
202103 -0.444 112.662 -0.458
202106 -0.081 111.769 -0.084
202109 0.078 112.215 0.081
202112 0.331 113.108 0.340
202203 -0.470 114.335 -0.478
202206 -0.146 114.558 -0.148
202209 -0.066 115.339 -0.067
202212 0.382 115.116 0.386
202303 -0.224 115.116 -0.226
202306 -0.105 114.558 -0.107
202309 -0.228 115.339 -0.230
202312 0.407 114.781 0.412
202403 -0.177 115.227 -0.179
202406 -0.330 114.781 -0.334
202409 0.106 115.785 0.106
202412 -0.213 114.893 -0.216
202503 -0.467 115.116 -0.472
202506 -0.550 114.907 -0.557
202509 -0.164 115.471 -0.165
202512 0.195 115.832 0.196
202603 -0.432 116.303 -0.432

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of ¥-0.44 mean?
Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) has a Cyclically Adjusted FCF per Share of ¥-0.44 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Jiangsu Lianhuan Pharmaceutical Co and its competitors.
Is Jiangsu Lianhuan Pharmaceutical Co's Cyclically Adjusted FCF per Share too high?
Jiangsu Lianhuan Pharmaceutical Co's current Cyclically Adjusted FCF per Share is ¥-0.44. Overall, Jiangsu Lianhuan Pharmaceutical Co has a GF Score™ of 63/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Lianhuan Pharmaceutical Co's Cyclically Adjusted FCF per Share compare to ZTS?
Jiangsu Lianhuan Pharmaceutical Co's Cyclically Adjusted FCF per Share of ¥-0.44 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Jiangsu Lianhuan Pharmaceutical Co and its competitors. Jiangsu Lianhuan Pharmaceutical Co's current Cyclically Adjusted FCF per Share is ¥-0.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Lianhuan Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥13.83, compared to a current price of ¥16.64 — trading 20.3% above its estimated fair value. The current Cyclically Adjusted FCF per Share is ¥-0.44. Jiangsu Lianhuan Pharmaceutical Co's overall GF Score™ is 63/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513), the current Cyclically Adjusted FCF per Share is ¥-0.44 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) Overvalued in 2026?

Based on GuruFocus' analysis, Jiangsu Lianhuan Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥16.64 is trading 20.3% above its estimated GF Value™ of ¥13.83. GuruFocus considers Jiangsu Lianhuan Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for SHSE:600513:

  • Cyclically Adjusted FCF per Share: ¥-0.44
  • GF Value™: ¥13.83 vs. price of ¥16.64 (20.3% above fair value)
  • GF Score™: 63/100 with 10 warning signs

No single metric tells the full story. See the SHSE:600513 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Jiangsu Lianhuan Pharmaceutical Co Business Description

Address No. 9, Jiankang 1st Road, Yangzhou Bio-Health Industry Park, Jiangsu Province, Yangzhou, Jiangsu, CHN, 225127
Jiangsu Lianhuan Pharmaceutical Co Ltd is engaged in producing benign prostatic hyperplasia, allergy and cardiovascular drugs. In the field of pharmaceutical manufacturing, the company's main products include several series such as urinary system drugs, antihistamines, cardiovascular drugs, steroid hormones, antibiotics, etc., covering chemical raw materials and injections, solid preparations and various drug dosage forms, including the national first-class new drug Apelite Tablets (Chuanliu).
63GF Score

Get the complete analysis for SHSE:600513

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥16.64
Price
¥13.83
GF Value